Abstract: An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities. A fusion protein or immunoconjugate includes the FGF21 polypeptide.

Abstract: An FGF21 polypeptide has one or more of the following properties: stable structure, long half-life, low immunogenicity, high biological activity, and enhanced glucose-lowering and lipid-lowering activities. A fusion protein or immunoconjugate includes the FGF21 polypeptide.

Abstract: A battery includes an electrolyte solution. The electrolyte solution includes ethyl butyrate, and a mass content of the ethyl butyrate in the electrolyte solution is c1; the battery includes an electrode assembly, the electrode assembly includes a positive electrode plate, a negative electrode plate, and a separator, and a thickness of the electrode assembly is a, in unit of mm; and a and c1 satisfy 0<c1/a?0.25. The battery of the present disclosure improves safety performance under fast charging conditions.

Abstract: This application provides a control method of a virtual skill performed by an electronic device. The method includes: rendering a skill control of a virtual scene, the skill control corresponding to a motion skill of a target virtual object; rendering a composite skill control containing a direction indication identification when a trigger operation for the skill control is received; and controlling the target virtual object to release the motion skill along a first direction according to a current property of the direction indication identification in the composite skill control in response to a first skill release instruction triggered on the composite skill control.

Abstract: A user interface display method and apparatus, a device, and a storage medium, in the field of graphical user interfaces. The method includes: displaying a virtual environment image, an operation control, and a minimap, the virtual environment image being an image in which a virtual environment around a virtual character, which is located in a virtual world, is observed from a perspective of the virtual character, wherein the minimap presents a thumbnail of the virtual world in which the virtual character is located, controlling, based on a control input via the operation control, activities of a virtual character in the virtual environment, and displaying, based on the virtual character being influenced by a target event in the virtual environment, the virtual environment image in a shielded state and the minimap in a blurred state.

Abstract: A method for controlling an object in a virtual scene for an electronic device includes: controlling, in response to a first interaction control instruction, a virtual object to perform an interactive operation indicated by the first interaction control instruction; controlling, in response to a second interaction control instruction for a copy skill, the virtual object to cast the copy skill including creating a copy of the virtual object in the virtual scene; controlling, in response to a third interaction control instruction, the copy to perform an interactive operation indicated by the third interaction control instruction; removing the copy from the virtual scene in response to that a disappearing condition of the copy of the virtual object is satisfied; and controlling, in response to a fourth interaction control instruction, the virtual object to perform an interactive operation indicated by the fourth interaction control instruction.

Abstract: An antibody, or an antigen-binding fragment thereof, or a chimeric antigen receptor having the ability of specifically recognizing CLDN18.2. The antibody or antigen-binding fragment thereof, or chimeric antigen receptor comprises at least one CDR sequence selected from the following or an amino acid sequence having at least 95% identity with it: the CDR sequence of light chain variable region shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9; the CDR sequence of heavy chain variable region shown in: SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.

Abstract: The present invention discloses a method for private set intersection in a smart city system, a device, and a storage medium. According to the present invention, a threshold secret sharing technology is adopted to share a private set among three parties, so that an intersection cardinality is hidden and security of private set intersection is improved. Before two parties perform the private set intersection, a blockchain is used to verify identities of the two parties, which protects security of data of the two parties to a certain extent. In addition, according to the present invention, the private set is divided into a plurality of subsets with labels, which implements an interaction manner with finer granularity. Therefore, compared with a private set intersection solution in a previous smart city system, the present invention is greatly improved in practicability, security, and other aspects.

Abstract: Fusing nanowire inks are described that can also comprise a hydrophilic polymer binder. such as a cellulose based binder. The fusing nanowire inks can be deposited onto a substrate surface and dried to drive the fusing process. Transparent conductive films can be formed with desirable properties.

Abstract: The present invention relates to a task processing method for a game session. The method includes: receiving a game spectating request from a first game terminal, obtaining a game screen of a spectated character corresponding to the game spectating request, and sending the game screen to the first game terminal; receiving request information from the first game terminal, where the request information includes at least one predetermined task; sending the predetermined task to at least one game terminal in the game session; in response to a determination operation received by any game terminal for the predetermined task, determining that a game character who meets a predetermined condition is an executor of the predetermined task; and based on an execution result of the predetermined task, allocating a game resource reward to a game account corresponding to the executor.

Abstract: The present invention relates to the technical field of network service, and in particular, to a user state switching method, a system, a device, a medium and a computer program product. The user state switching method comprises: a receiving step: receiving a switching request for a user state; a query step: querying the user state; a determination step: determining, on the basis of a finite state machine of the user state, whether to allow switching of the user state; an error return step: if the switching of the user state is not allowed, returning error information; a state switching step: if the switching of the user state is allowed, modifying and storing information of the user state, and switching the user state on the basis of the finite state machine. Can meet complex user state switching design requirements, can perform self-repair of user state abnormalities, and can push the user's state to other users in real time.

Abstract: Provided is a set of viral vectors, comprising: a first viral vector that carries a first nucleic acid molecule encoding an envelope protein, and a second viral vector that carries a second nucleic acid molecule encoding a fusion protein, the fusion protein comprising: a single-chain antibody capable of binding to CD28 or CD3, and a C-terminal domain, comprising a transmembrane region and an intracellular region, of the envelope protein. The C terminal of the single-chain antibody is connected to the N terminal of the C-terminal domain of the envelope protein, and the envelope protein and the fusion protein are in a non-fusion form. Also provided are a method for obtaining a lentivirus and an obtained lentivirus, a method for introducing a lentivirus into an unactivated T lymphocyte, a method for expressing a target gene, a method for obtaining a CAR-T cell and an obtained CAR-T cell, a pharmaceutical composition, and a use thereof.

Abstract: Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.

Abstract: Methods for processing deposited metal nanowire inks with metal ions are used to form fused metal nanostructured networks. The metal nanowire inks include a hydrophilic polymer binder, such as a cellulose based binder. The metal nanowire inks can be deposited onto a substrate surface and dried to drive the fusing process. Transparent conductive films can be formed with desirable properties.

Abstract: A fusion protein comprises an Fc variant and a GDF15 active domain, wherein the Fc variant has amino acid substitutions at position 356 and/or position 439 of the IgG Fc according to EU numbering and still has the ability to form homodimer. By fusing the Fc variant with the GDF15 active domain, the Fc-GDF15 fusion protein has significantly improved physicochemical properties and recombinant expression levels, has in vitro activity equivalent to or better than natural GDF15 molecules, and has significantly prolonged in vivo circulating half-life, which can support the dosing frequency of once every two weeks or even once a month.

Abstract: Provided is a fusion protein containing GLP-1 and FGF21 linked through an immunoglobulin Fc portion. Each of the GLP-1 and FGF21 can be substituted with its analogues or variants and, the Fc portion, which can be derived from IgG4, can include substitutions that further enhance the fusion protein's stability and activity. These fragments can be linked together through peptide linkers. The fusion protein can be used clinically to reduce glucose and lipid levels and body weight.